Today: 27 January 2026
Subscribe
Browse Category

Investment Analysis News 8 October 2025 - 10 October 2025

Levi Strauss Shocks Wall Street: Denim Demand Soars, Forecast Raised – Why LEVI Stock Still Slipped

Levi Strauss Shocks Wall Street: Denim Demand Soars, Forecast Raised – Why LEVI Stock Still Slipped

Blockbuster Q3 Earnings – Sales Beat and Outlook Raised Levi Strauss & Co. delivered strong third-quarter 2025 results, topping estimates and defying retail sector headwinds. Revenue for Q3 (June–August 2025) hit $1.54 billion, up 7% year-on-year and slightly above analyst expectations of ~$1.50 billion Reuters Tipranks. Adjusted earnings were $0.34 per share, a penny higher than a year ago and beating the $0.31 consensus estimate Tipranks. The company achieved broad-based growth across…
10 October 2025
··
Costco Stock Surges Amid Retail Gloom – Will $900+ Shares Keep Climbing?

Costco Stock Soars Amid Retail Gloom – What’s Driving the Rally and Will It Last?

Stock Price & Recent Performance Costco’s stock has been on a long-term upward climb, and 2025 is no exception – though it hasn’t been a smooth ride. After a strong rally in the first half of the year, Costco (COST) shares reached an intraday record high around $1,078earlier in 2025 ts2.tech. Enthusiasm was fueled by robust sales growth and a broader…
9 October 2025
····
CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

Company Background & Business Model Cipher Mining is a pure-play Bitcoin miner that specializes in large-scale, energy-efficient data-center mining ts2.tech. It locates facilities “behind the meter” at low-cost renewable power sites in West Texas ts2.tech. Its flagship “Black Pearl” complex (Odessa, TX) is a 150 MW facility serving both Bitcoin mining and high-performance computing (HPC) ts2.tech. As of mid-2025, Cipher had…
9 October 2025
····
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015 Renaissancecapital. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listing Stockanalysis. Turn’s mission is to “turn the tides” in medicine by developing technologies that heal, not just manage, challenging traditional treatments Benzinga. CEO Bradley…
9 October 2025
····
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today,…
9 October 2025
···
PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

Key Data & Metrics (as of October 9, 2025) Metric Value Stock Price (Oct 8, 2025) $138.84 (close) MarketbeatDown ~6% in past month; ~–6% YTD Finviz Indexbox 52-Week Range Low $127.60 – High $177.48 Businessinsider Market Capitalization ~$193 Billion Businessinsider Forward P/E (2025E) ~17.5× (near industry avg ~17.5×) Finviz Trailing P/E (TTM) ~21.8× Businessinsider PEG Ratio (Forward) ~3.5 (industry ~2.3)…
9 October 2025
····
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s Strong Quarter Signals a Turnaround Tilray Brands kicked off its fiscal 2026 with better-than-expected results, signaling that aggressive cost-cutting and diversification efforts are bearing fruit. The company’s Q1 FY2026 revenue hit $209.5 million, a 5% increase over last year’s quarter Stocktitan. More impressively, Tilray managed to swing to a net profit of $1.5 million (or $0.00 per share) –…
9 October 2025
····
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Stock Price Surge: From IPO to Record Highs Tempus AI’s stock has been on a remarkable tear since its mid-2024 IPO. The Chicago-based healthtech firm – founded in 2015 by Eric Lefkofsky (of Groupon fame) – went public in June 2024 at around $21 per share, and the price has since quadrupled ts2.tech. After a steady climb through 2024, momentum…
9 October 2025
··
UiPath’s Automation Stock Soars on AI Buzz – Latest PATH Analysis & Outlook

UiPath’s Automation Stock Soars on AI Buzz – Latest PATH Analysis & Outlook

Stock Performance: Hitting New Highs on AI Momentum UiPath’s stock has been on a tear in early October 2025, propelled by excitement around artificial intelligence. On October 8, PATH jumped 5.13% to close at $15.58 – its highest closing price since May 2024 Stocktwits. This capped a rapid climb from the ~$12–13 range just a week earlier. In fact, shares gapped up in…
9 October 2025
···
CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

Sources: Official company reports and press releases; Yahoo Finance and Zacks Investment Research; Reuters and CNBC interviews; TS2 Tech stock analysis and cybersecurity news ts2.tech Nasdaq Financialcontent Marketbeat ts2.tech Siliconangle ts2.tech. These provide the latest financial data, expert commentary, and industry context as of October 8, 2025.…
8 October 2025
····
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote…
8 October 2025
···
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever…
8 October 2025
···
1 … 252 253 254 255 256 257

Stock Market Today

  • S&P 500 Futures Flat After Gains Ahead of Major Tech Earnings and Fed Decision
    January 26, 2026, 6:38 PM EST. S&P 500 futures were little changed Monday evening following a positive start to earnings week. The S&P 500 rose 0.5% in regular trading, boosted by technology giants Apple, Meta, and Microsoft ahead of their earnings reports later this week. Dow futures declined 0.3%, pressured by nearly 9% drop in UnitedHealth shares after Medicare Advantage payment hikes were kept minimal by regulators. President Trump's tariff increase on South Korean goods also weighed on markets. Investors now await the Federal Reserve's rate decision, expected to hold at 3.5%-3.75%, with potential rate cut signals eyed for later in 2026. Over 90 S&P 500 companies, including major tech stocks, will report earnings this week, with about 75% of firms beating expectations so far this season.
Go toTop